Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Hyperinsulinemia: early-phase trial registry

4 of 6 indexed Hyperinsulinemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Hyperinsulinemia: 6 US clinical trials tracked, 4 recruiting.

Hyperinsulinemia is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Columbia University, running 2 of these trials.

Enrollment posture brief

Registry condition hyperinsulinemia

OPEN 4 | RECR 67% | LATE 0 | EARLY 2 | RANK #2866 | SPON 2

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Hyperinsulinemia (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Hyperinsulinemia

Hyperinsulinemia lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hyperinsulinemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hyperinsulinemia is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hyperinsulinemia research.

    Columbia University accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Hyperinsulinemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 15 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.

  4. Hyperinsulinemia splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Hyperinsulinemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dietary Modification Behavioral
1 trials
Dextrose Drug
1 trials
GnRH Drug
1 trials
Fed Trial Other
1 trials
Fasting Trial Other
1 trials
Intralipid Drug
1 trials
Heparin Drug
1 trials
Diazoxide, 3 mg/kg per dose Drug
1 trials

US sites by state

Facility locations filed on Hyperinsulinemia trials. A trial with sites in several states counts in each.

New York 2 trials
Michigan 1 trials
Maryland 1 trials
Indiana 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hyperinsulinemia page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperinsulinemia condition card totals 6 registered trials; most-linked intervention Dietary Modification; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.